Metsera, a clinical-stage biotechnology startup that develops drugs for obesity and metabolic diseases, launched on Thursday with what it described as a “broad portfolio” of weight-loss ...

Biopharma startup Metsera turned heads in April when it emerged from stealth, announcing $290 million in funding from prestigious backers—an all-star roster of scientists and executives—and a ...

Any company hoping to make headway in the market for obesity therapies will need deep pockets, so it’s an encouraging sign that start-up Metsera has launched with an impressive $290 million in ...

(RTTNews) - Amneal Pharmaceuticals (AMRX) and Metsera have entered into a collaboration agreement to enable the efficient development and large-scale supply of a portfolio of new weight loss ...

BRIDGEWATER, N.J. & NEW YORK--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, and ...

Amneal Pharmaceuticals (NASDAQ:AMRX) entered agreement with Metsera to enable development and large-scale supply of a portfolio of new weight loss medicines globally. Amneal will construct ...

Delilah Alvarado Obesity drug startup Metsera said Tuesday it has signed a deal with manufacturing firm Amneal Pharmaceuticals to produce, package and supply its weight-loss therapies in the U.S ...

The revision follows a recent collaboration between Amneal and Metsera, marking Amneal's entry into the GLP1 space for the U.S. and European markets, as well as establishing the company as a ...

Metsera gains high-quality, efficient, large-scale manufacturing capabilities for its portfolio to enable rapid product development and anticipated commercial launches Amneal Pharmaceuticals, Inc.

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Moderna has dosed the first U.S. participants in a ...

Amneal to construct state-of-the-art manufacturing facilities and utilize existing manufacturing network to ensure supply of Metsera’s portfolio of novel injectable and oral development programs, ...